Both the PROTECT and the Eu2P Consortium promote the exchange of postgraduate training opportunities among its partners and other centres.
The goal of PROTECT is to strengthen the monitoring of the benefit-risk of medicines in Europe. This will be achieved by developing a set of innovative tools and methods that will enhance the early detection and assessment of adverse drug reactions from different data sources, and enable the integration and presentation of data on benefits and risks. PROTECT consists of 31 public and private partners coordinated by the European Medicines Agency.
Eu2P is a unique education & training programme in pharmacovigilance and pharmacoepidemiology. Eu2P is designed to enhance the understanding of medicines benefit and risk to improve health protection. Eu2P is driven by a European consortium of seven Universities, the European and French Medicines Agencies and fifteen pharmaceutical companies.
Both PROTECT and Eu2P receive funding from the Innovative Medicines Initiative Joint Undertaking.